Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Blinded, Placebo-Controlled, Multicenter, Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BG9924 When Given in Combination With Methotrexate to Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to DMARD Therapy

NCT00292422 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT00292422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00292422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Blinded, Placebo-Controlled, Multicenter, Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BG9924 When Given in Combination With Methotrexate to Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to DMARD Therapy
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2005
Completion date
May 31, 2007
Enrollment
50 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis